ORIC Pharmaceuticals Expects Initial 1b Data For 3 Ongoing Trials In H1 2023
Initial Phase 1b data for three ongoing clinical trials expected in second half of 2023: ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2-mutated cancers, and ORIC-944 in prostate cancer
Development candidate